A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003,
and to determine the recommended dose of phase II clinical study (RP2D) in the indication of
locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy
of SI-B001+SI-B003 combination with or without chemotherapy in patients with locally advanced
or metastatic non-small cell lung cancer.